Why Binding Isn't Enough: Predicting Function in GPCR Drug Discovery

In this webinar, SandboxAQ's team will show how AQState addresses a critical gap in GPCR drug discovery. GPCRs are signaling proteins that act as molecular switches — an agonist activates the receptor, an antagonist blocks it. That distinction determines therapeutic effect, and an error here can reverse it entirely.

Standard virtual screening ranks compounds by predicted binding affinity, but leaves a critical question unanswered: will this compound activate the receptor or block it? Without that answer, teams must run costly experimental assays or follow-on analyses to separate agonists from antagonists — steps that filter the hit list rather than improve it.

AQState predicts both binding affinity and mechanism of action before experimental testing begins, running in under one minute per molecule. In retrospective GPCR benchmarking, this achieved 79% accuracy, 83% specificity, and a 43% reduction in agonist misclassifications compared to the previous method.

Key Learning Objectives:

• Why binding affinity alone fails GPCR programs and what to do instead
• How AQState delivers both speed and accuracy
• Where AQState fits in a GPCR discovery workflow